Defying broader market volatility and economic uncertainty, CVS Health (NYSE: CVS) has delivered a stellar performance in 2025, with its shares surging approximately 76% year-to-date as of mid-October, significantly outpacing the market.
Despite this impressive rally, a compelling narrative is emerging on Wall Street: the healthcare giant appears significantly undervalued. With a forward price-to-earnings (P/E) ratio of just 10.7, CVS trades at a substantial discount to the healthcare sector’s average of 17.3. This key valuation metric suggests that even after its powerful run, the stock may still be cheap relative to its industry peers and operational scale.
The recent stock momentum has been directly catalyzed by financial results that surpassed market expectations. For the second quarter, CVS reported total revenue of $98.9 billion, a robust 8.4% increase year-over-year.
While the adjusted earnings per share of $1.81 slightly missed the $1.83 from a year ago, the strong top-line growth captured investor attention. The performance was notably driven by strength in the Health Care Benefits segment, buoyed by higher revenues from government insurance programs. Contributing factors also included solid results from the retail pharmacy business and positive impacts from revisions in risk adjustment estimates.
This performance marks a significant turnaround for the company’s Medicare Advantage unit, which had previously been a drag on profitability with an operating margin as low as -4.5% to -5% last year.
To fundamentally address profitability challenges in its insurance business, CVS has embarked on a clear strategic shift: moving away from pure membership growth toward enhancing profit margins, including a deliberate contraction of certain Medicare Advantage plans.
Analysts point to CVS’s extensive and integrated ecosystem as its core, long-term competitive advantage, which is difficult for competitors to replicate.
Despite ongoing short-term challenges in its health insurance segment, CVS is actively executing its strategic recalibration. Given its current discounted valuation, better-than-expected operational performance, and a clear long-term growth strategy, many market observers believe CVS stock still holds substantial potential for investors with a long-term horizon, even after its significant price appreciation this year.
The company’s extensive reach in the healthcare sector, stable partnerships, and the tailwind of rising healthcare spending from an aging population are cited as key supportive factors for its enduring appeal.
